New Directors elected at Nobel Biocare

12/11/2000 11:58 AM EST

At today's extraordinary shareholders' meeting, Ms Heliane Canepa and Dr
Ernst Thomke were elected as directors. Lars Ingelmark had decided to
resign from the board. The number of directors has thus been increased
from eight to nine.

Directors Ms Heliane Canepa and Dr Ernst Thomke were proposed by the Swiss
medtech fund BB Medtech AG which is listed in Switzerland and on Neuer
Markt in Germany. Shareholders representing approximately 20% of the
outstanding shares and votes supported the nomination.

The Nobel Biocare board of directors represents in depth industrial
knowledge and vast international experience that is in line with Nobel
Biocare's international business orientation and owner structure.

Ms Heliane Canepa, Switzerland, is the former CEO of the cardiology
company Schneider and is currently a board member of BB Medtech AG,
Migros, Phonak Holding Ltd, Switzerland, and Intratherapeutics, USA. Dr
Ernst Thomke, Switzerland, has vast experience of the medtech sector and
is the Chairman of BB Medtech AG, BB Biotech AG and Metaux Précieux SA
METALOR, Switzerland. He is also a board member of Phonak Holding Ltd,
Switzerland.

Other board members elected by the Annual General Meeting are:
Kenneth A Darienzo, USA, former CEO of Steri-Oss Inc., Jan Ekberg, former
CEO and Chairman of Pharmacia Inc., Roger Holtback, CEO of Bure Equity AB,
Jan Kvarnström, senior adviser to companies including the venture capital
company 3i Plc. and former CEO of Esselte AB and Securum AB, Håkan
Larsson, Chairman of Schenker AG, Germany, T. Michael Long, USA, Partner
in Brown Brothers Harriman & Co, Private Bankers, New York and Jack
Forsgren, CEO of Nobel Biocare AB.

Gothenburg, December 11, 2000

NOBEL BIOCARE AB

For more information, please contact:

Jack Forsgren, CEO, telephone +46 31 81 88 58, or Jan H Johansson, General
Counsel, telephone +46 31 81 88 29, Nobel Biocare AB.

Nobel Biocare is an innovative, medical devices company, whose core
business comprises dental implants and dental prosthetics. The company's
® ®
product systems for dental implants, Brånemark System and Steri-Oss , are
world leaders and have a global market share of around 40%.
®
The company's other product line, Procera , is a unique, IT-based process
for the industrial production of dental prosthetics. The system has been
launched very successfully in 22 countries.
Nobel Biocare has around 1,190 employees and, in 1999, turnover totaled
SEK 1,738 million. The company's headquarters are located in Gothenburg,
Sweden, while production takes place in Sweden and the USA. Nobel Biocare
has its own sales companies in 25 countries.


Nobel Biocare AB, Box 5190, SE-401 26 Gothenburg, Sweden
Telephone +46 31 81 88 00. Fax +46 31 16 31 52
e-mail:  
www.nobelbiocare.com